Clinical Research Directory

Inclusion Criteria: * No life threatening injuries resulting from the traumatic accident * No evidence of sepsis * Acute cervical or thoracic SCI with ASIA Impairment Scale Grade A, B, or C od admission. * Non-penetrating SCI at neurologic level from C2 to C8 or T1 to T12 Exclusion Criteria: * Unconsciousness or other mental impairment that prevents neurological assessment within the first 8 hours * Acute SCI with ASIA Impairment Scale grade D or E * Currently involved in another non-observational SCI research study or receiving another investigational drug * History of hypersensitivity to sulfonylureas, in particular glyburide, or any of its components * Any condition likely to result in the patient's death within the next 12 months * Severe renal disorder from the patient's history (e.g. dialysis) or baseline eGFR of \< 30 mL/min/1.73 m2 * Known severe liver disease, or ALT \> 3 times upper limit of normal or bilirubin * Blood glucose \<55 mg/dL at enrollment or immediately prior to administration of DiaBeta, or a clinically significant history of hypoglycemia * Acute ST elevation myocardial infarction, and/or acute decompensated heart failure, and/or QTc \> 520 ms, and/or known history of cardiac arrest (PEA, VT, VF, asystole), and/or admission for an acute coronary syndrome, myocardial infarction, or coronary intervention (percutaneous coronary intervention or coronary artery surgery) within the past 3 months * Known G6PD enzyme deficiency